These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 38152694

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R, Vaghi G, Allena M, Ghiotto N, Guaschino E, Martinelli D, Ahmad L, Corrado M, Bighiani F, Tanganelli F, Bottiroli S, Cammarota F, Sances G, Tassorelli C.
    J Headache Pain; 2022 Sep 17; 23(1):123. PubMed ID: 36115947
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE-The First Italian Multicenter, Prospective, Real-Life Study.
    Barbanti P, Orlando B, Egeo G, d'Onofrio F, Doretti A, Messina S, Autunno M, Messina R, Filippi M, Fiorentini G, Rotondi C, Bonassi S, Aurilia C.
    Brain Sci; 2024 Jun 30; 14(7):. PubMed ID: 39061413
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review.
    Aditya S, Rattan A.
    Saudi J Med Med Sci; 2023 Jun 30; 11(1):11-18. PubMed ID: 36909005
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Additional effect of erenumab for patients with chronic migraine treated with onabotulinumtoxin A-real-world data from a preliminary cohort study.
    Koelsche T, Nikolov P, Koska V, Ingwersen J, Jansen R, Arat E, Meuth SG, Albrecht P, Lee JI.
    Front Neurol; 2024 Jun 30; 15():1370503. PubMed ID: 38988600
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis.
    Armanious M, Khalil N, Lu Y, Jimenez-Sanders R.
    J Pain Palliat Care Pharmacother; 2021 Mar 30; 35(1):1-6. PubMed ID: 33125303
    [Abstract] [Full Text] [Related]

  • 35. Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series.
    Silvestro M, Tessitore A, Scotto di Clemente F, Tedeschi G, Russo A.
    Headache; 2020 Jun 30; 60(6):1187-1195. PubMed ID: 32359106
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study.
    Alsaadi T, Suliman R, Santos V, Al Qaisi I, Carmina P, Aldaher B, Haddad S, Bader Y.
    Neurol Ther; 2024 Apr 30; 13(2):465-473. PubMed ID: 38361080
    [Abstract] [Full Text] [Related]

  • 38. Therapies targeting CGRP signaling for medication overuse headache.
    Koumprentziotis IA, Mitsikostas DD.
    Curr Opin Neurol; 2022 Jun 01; 35(3):353-359. PubMed ID: 35674079
    [Abstract] [Full Text] [Related]

  • 39. Impact of duration of chronic migraine on long-term effectiveness of monoclonal antibodies targeting the calcitonin gene-related peptide pathway-A real-world study.
    Ornello R, Baldini F, Onofri A, Rosignoli C, De Santis F, Burgalassi A, Chiarugi A, Geppetti P, Sacco S, Iannone LF.
    Headache; 2024 Jul 16. PubMed ID: 39012070
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.